Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Next Previous
X
Search
Trial Profile

Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Unoprostone (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors R-Tech Ueno

    • Most Recent Events

    • 28 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2015 Based on top-line data from this trial, Sucampo has decided not to continue development of unoprostone and will return all licenses to R-Tech Ueno, according to a media release.
    • 09 Mar 2015 Preliminary top-line results published in R-Tech Ueno media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top